HC Wainwright & Co. Reiterates Buy on Reneo Pharmaceuticals, Maintains $30 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Gobind Singh has reiterated a 'Buy' rating on Reneo Pharmaceuticals (NASDAQ:RPHM) and maintained a $30 price target.

September 08, 2023 | 11:00 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Reneo Pharmaceuticals' stock may see positive movement as HC Wainwright & Co. maintains a 'Buy' rating and a $30 price target.
Analyst ratings and price targets can significantly influence investor sentiment and stock prices. The reiteration of a 'Buy' rating and a $30 price target by HC Wainwright & Co. indicates their positive outlook on Reneo Pharmaceuticals, which could lead to increased investor interest and a potential rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100